Latest Chroma Therapeutics Ltd. Stories
SEATTLE and OXFORD, England, March 14, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) and Chroma Therapeutics Ltd. ("Chroma") announced today that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in...
- A stinking tobacco.
- Offal; waste animal product; organic matter unfit for consumption.